WA
AMLX icon

Westfuller Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Westfuller Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7K Hold
819
– – 0.01% 424
2026
Q1 		$11.4K Hold
819
– – ﹤0.01% 427
2025
Q4 		$9.89K Buy
+819
New +$11.1K ﹤0.01% 472

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Westfuller Advisors's AMLX Position: Q2 2026 in Review

Westfuller Advisors held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 819 shares worth $14.7K. The position accounts for 0.01% of the portfolio, ranked #424.

Westfuller Advisors first reported a position in AMLX in Q4 2025 and has held it in 3 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Westfuller Advisors held 819 shares of Amylyx Pharmaceuticals worth $14.7K as of Q2 2026.
  • Westfuller Advisors left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
  • Amylyx Pharmaceuticals made up 0.01% of Westfuller Advisors's portfolio in Q2 2026, its #424 holding.
  • Westfuller Advisors first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Westfuller Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.